DUAL LSD1/HDAC INHIBITORS

The present disclosure provides a compound of Formula (I), its analogs, tautomeric forms, stereoisomers, enantiomers, diastereomers and pharmaceutically acceptable salts thereof. The present disclosure also provides a process for preparing the compounds of Formula (I), its analogs, tautomeric forms,...

Full description

Saved in:
Bibliographic Details
Main Authors GAJENDRAN, Chandru, SIVANANDHAN, Dhanalakshmi, RASTELLI, Luca, SADHU, Naveen, SRIDHARAN, Rajagopal
Format Patent
LanguageEnglish
French
Published 14.09.2023
Subjects
ACYCLIC OR CARBOCYCLIC COMPOUNDS
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present disclosure provides a compound of Formula (I), its analogs, tautomeric forms, stereoisomers, enantiomers, diastereomers and pharmaceutically acceptable salts thereof. The present disclosure also provides a process for preparing the compounds of Formula (I), its analogs, tautomeric forms, stereoisomers, enantiomers, diastereomers and pharmaceutically acceptable salts thereof. The compounds of Formula (I) modulates MYC or coREST, in a subject in need thereof. The compounds of Formula (I) inhibits HDAC enzymes or LSD1 enzymes, or both HDAC enzymes and LSD1 enzymes. The compound of Formula (I) is an epigenetic modulating agent with a novel mechanism of action that target MYC amplification in multiple neuroendocrine tumors types. La présente divulgation concerne un composé de Formule (I), ses analogues, ses formes tautomères, ses stéréoisomères, ses énantiomères, ses diastéréomères et ses sels pharmaceutiquement acceptables. La présente divulgation concerne également un procédé de préparation des composés de Formule (I), de ses analogues, formes tautomères, stéréoisomères, énantiomères, diastéréomères et sels pharmaceutiquement acceptables de ceux-ci. Les composés de Formule (I) modulent MYC ou coREST, chez un sujet en ayant besoin. Les composés de Formule (I) inhibent les enzymes HDAC ou les enzymes LSD1, ou les deux enzymes HDAC et les enzymes LSD1. Le composé de Formule (I) est un agent de modulation épigénétique avec un nouveau mécanisme d'action qui cible l'amplification de MYC dans de multiples types de tumeurs neuroendocrines.
Bibliography:Application Number: WO2023IN50233